Immunome, Inc.
IMNMNASDAQHealthcare● Active
$18.61
+$0.03(+0.16%)
Market Cap$1.8B
P/E Ratio—
52W High$27.65
52W Low$7.96
Immunome, Inc. (IMNM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IMNM · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $6.94M | $9.04M | $14.02M | $0.00M | $0.00M |
| Cost of Revenue | $2.96M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $3.99M | $9.04M | $14.02M | $0.00M | $0.00M |
| Gross Margin %(computed) | 57.43% | 100.00% | 100.00% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $174.33M | $129.54M | $23.09M | $23.27M | $14.11M |
| G&A Expenses | $43.77M | $32.95M | $19.66M | $13.63M | $11.09M |
| Total Operating Expenses | $218.10M | $314.84M | $123.55M | $36.90M | $25.20M |
| Operating Income | ($214.11M) | ($305.80M) | ($109.53M) | ($36.90M) | ($25.20M) |
| Operating Margin %(computed) | — | — | -781.35% | — | — |
| Interest Income | $11.72M | $12.84M | $2.72M | $0.01M | $0.01M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.01M | $0.01M |
| Income Before Tax | ($212.39M) | ($292.96M) | ($106.81M) | ($36.90M) | ($24.71M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($212.39M) | ($292.96M) | ($106.81M) | ($36.90M) | ($24.71M) |
| Net Margin %(computed) | — | — | -761.92% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.43 | $-5.00 | $-5.38 | $-3.09 | $-2.14 |
| Wtd Avg Shares | 87.35M | 58.64M | 19.84M | 12.13M | 11.54M |
| EBITDA | ($211.16M) | ($151.35M) | ($28.00M) | ($36.27M) | ($24.45M) |
| EBITDA Margin %(computed) | — | — | -199.74% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Immunome, Inc. data
About Immunome, Inc. (IMNM) Income Statement
Immunome, Inc. (IMNM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IMNM reported revenue of $0.01B, gross profit of $0.00B (gross margin 57.43%), and net income of ($0.21B) — a net profit margin of -3059.99%.
Frequently asked questions
IMNM · 4 questionsImmunome, Inc. (IMNM) reported revenue of $0.01B for 2025, down 23.2% year-over-year.
IMNM revenueIMNM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08